TL/DR –
GE HealthCare has announced a Distribution and Services Agreement (DSA) with CardioNavix to provide its cardiac PET imaging agent, Flyrcado, to hospitals and outpatient practices nationwide. The collaboration is expected to accelerate adoption of Flyrcado, which has demonstrated higher diagnostic efficacy than SPECT MPI in detecting coronary artery disease. The initial roll-out of Flyrcado will begin in late 2025, with broader expansion planned for 2026.
GE HealthCare Collaborates with CardioNavix to Expand Cardiac PET Imaging in the U.S.
GE HealthCare has entered a Distribution and Services Agreement (DSA) with CardioNavix, a division of CDL Nuclear Technologies that offers comprehensive cardiac positron emission tomography (PET) imaging solutions. Through this, GE HealthCare seeks to extend the accessibility of Flyrcado (flurpiridaz F18) injection, its innovative cardiac PET imaging agent, to U.S. patients, especially those in private cardiology practices and imaging facilities.
PET myocardial perfusion imaging (MPI) constitutes about 5-10% of the estimated 6 million MPI procedures done in the U.S. annually. This technique is increasingly adopted by U.S. cardiology practices. The recent partnership is predicted to further enhance the use of Flyrcado, which showed superior diagnostic performance than SPECT MPI for detecting coronary artery disease in the Phase III AURORA trial.
“Our partnership with CardioNavix marks a significant milestone in making Flyrcado accessible to patients across various care settings,” commented Eric Ruedinger, Vice President and General Manager of GE HealthCare’s Pharmaceutical Diagnostics division. “CDL Nuclear Technologies is a well-trusted name in private cardiology and nuclear imaging, signalling our shared optimism in Flyrcado’s potential.”
“Our collaboration with GE HealthCare allows us to introduce Flyrcado to private practice cardiology as the first distributor,” said Lon Wilson, CEO of CDL Nuclear Technologies. “Our customer sites support approximately 220,000 patient procedures annually with comprehensive cardiac PET solutions, and this number continues to grow.”
The DSA aligns with GE HealthCare’s long-term strategy to establish the necessary capabilities for Flyrcado’s success in outpatient settings. The initial roll-out will kick off in late 2025 and extend into wider expansion in 2026.
For more information, visit www.gehealthcare.com.
—
Read More Health & Wellness News ; US News